Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study

Auteurs

Janice M. Mehnert, Emily Bergsland, Bert H. O’Neil, Armando Santoro, Jan H. M. Schellens, Roger B. Cohen, Toshihiko Doi, Patrick A. Ott, Michael J. Pishvaian, Igor Puzanov, Kyaw L. Aung, Chiun Hsu, Christophe Le Tourneau, Antoine Hollebecque, Elena Élez, Kenji Tamura, Marlena Gould, Ping Yang, Karen Stein, Sarina A. Piha‐Paul